E D Danilenko
Overview
Explore the profile of E D Danilenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Development of Drugs Based on High-Polymeric Double-Stranded RNA for Antiviral and Antitumor Therapy
Danilenko E, Belkina A, Sysoeva G
Biochem Mosc Suppl B Biomed Chem
. 2020 Apr;
13(4):308-323.
PMID: 32288939
-The review summarizes literature data on the development of drugs based on natural and synthetic high-polymeric double-stranded RNA (dsRNA), their antiviral, immunoadjuvant, and antitumor properties. Special attention is paid to...
2.
Danilenko E, Belkina A, Sysoeva G
Biomed Khim
. 2019 Aug;
65(4):277-293.
PMID: 31436169
The review summarizes literature data on the development of drugs based on natural and synthetic high-polymeric double-stranded RNA, and their antiviral, immunoadjuvant and antitumor properties. Special attention is paid to...
3.
Lebedev L, Danilenko E, Telegina Y, Zaitsev B
Biomed Khim
. 2015 Nov;
61(5):652-6.
PMID: 26539876
A novel drug for treatment of bone metastases based on human recombinant tumor necrosis factor (TNF-alpha) has been designed. The drug is a molecular structure containing yeast double-stranded ribonucleic acid...
4.
Skarnovich M, Shishkina L, Kabanov A, Mazurkova N, Danilenko E, Masycheva V, et al.
Zh Mikrobiol Epidemiol Immunobiol
. 2011 Dec;
(5):79-82.
PMID: 22145356
Aim: Study of possibility of treatment-prophylaxis effect increase during combined administration of ridostin and tamiflu in experiments in mice infected with highly pathogenic influenza virus strain A/chicken/Kurgan/05/2005 (H5N1). Materials And...
5.
Danilenko E, Gamalei S, Bateneva A, Sysoeva G, Levagina G, Masycheva V
Zh Mikrobiol Epidemiol Immunobiol
. 2011 Aug;
(3):57-61.
PMID: 21809646
Aim: Evaluation of composite formulation of yeast double stranded RNA with polyglucinum (dsRNA-PG) effect on non-specific antiviral resistance factors in mice in comparison with commercial formulation Ridostin. Materials And Methods:...
6.
Gamaley S, Bateneva A, Sysoeva G, Danilenko E, Lebedev L, Masycheva V
Bull Exp Biol Med
. 2011 Jan;
149(3):320-3.
PMID: 21246092
Antitumor activity of TNF-α incorporated in nanoparticles (VLP-TNF-α) and dynamics of its accumulation and elimination from the blood and tumor tissue were studied in ICR mice. The VLP-TNF-α preparation exhibited...
7.
Bateneva A, Babenko O, Danilenko E, Poryvaev V, Karpyshev N, Goncharova E, et al.
Eksp Klin Farmakol
. 2010 Apr;
73(2):18-21.
PMID: 20369596
Cytotoxic properties of a liposomal form of the HLDF6 hexapeptide, representing an HL-60 cell differentiation factor fragment, have been studied on a murine primary lymphosarcoma cell culture. It is established...
8.
Danilenko E, Sysoeva G, Ustimenko S, Samukov V, Kostanian I, Masycheva V
Vopr Onkol
. 2010 Mar;
55(6):757-60.
PMID: 20210021
A study of antitumor properties of HLDF-6 was carried out in DBA/2 mice with transplantable ascites lympholeukemia P-388 as well as in tumor cell culture. Immunomodulating characteristics were evaluated. Five-fold...
9.
Asratian A, Danilenko E, Kazarian S, Chubarov V, Mardanly S
Zh Mikrobiol Epidemiol Immunobiol
. 2010 Jan;
(5):22-7.
PMID: 20063788
Aim: Identification of clinico-epidemiologic features of pareneteral hepatites (HB and HC) and herpesvirus infections (cytomegalovirus, CMVand herpes simplexvirus, HSV) duringpregnancy. Materials And Methods: Two hundred pregnant women as well as...
10.
Sysoeva G, Fadina V, Danilenko E, Samukov V, Kostanyan I, Masycheva V
Bull Exp Biol Med
. 2009 Jun;
147(2):229-32.
PMID: 19513428
A six-member HLDF6 peptide, fragment of HL-60 cell differentiation factor, exhibited antimetastatic and immunomodulating effects.